Showing results (61-70 of 77) with videos related to
Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUEMichael C Heinrich, Jean-Yves Blay, Hans Gelderblom, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)Matthew Ingham, Jacob B Allred, Li Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2021
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1Sant P Chawla, Brian A Van Tine, Seth M Pollack, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2024
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid HemangioendotheliomaScott M Schuetze, Karla V Ballman, Rachel Heise, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2020
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to PembrolizumabEmily Z Keung, Melissa Burgess, Ruth Salazar, et al.The Lancet. Oncology|October 9, 2020
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket studyMrinal Gounder, Patrick Schöffski, Robin L Jones, et al.The Lancet. Oncology|October 10, 2017
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trialHussein A Tawbi, Melissa Burgess, Vanessa Bolejack, et al.European Journal of Cancer (Oxford, England : 1990)|August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label studyHans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.The New England Journal of Medicine|December 22, 2018
Sorafenib for Advanced and Refractory Desmoid TumorsMrinal M Gounder, Michelle R Mahoney, Brian A Van Tine, et al.Nature Medicine|January 5, 2024
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trialMichael C Heinrich, Robin L Jones, Suzanne George, et al.Pageof 8